Clinical Trials

Text Size A A

E-Mail to a Friend






secret  Click to Play Audio


Leukemia

Quizartinib for Relapsed or Refractory Acute Myeloid Leukemia (2623)
A Phase 2, Randomized, Open-label study of the Safety and Efficacy of Two Doses of Quizartinib (AC220; ASP2689) in Subjects with FLT3-ITD Positive Relapsed or Refractory Acute Myeloid Leukemia (AML)
Status Conditions Phase Study ID
Closed Acute Myeloid Leukemia Phase II 2623
NCT01565668
Summary

This study will evaluate two doses of Quizartinib in patients with relapsed or refractory acute myeloid leukemia who are also FMS-like tyrosine kinase - internal tandem duplication ( FLT3-ITD) positive. Patient will be randomly assigned in a 1:1 ratio to one of two treatment arms. Both treatment arms will receive Quizartinib but at different doses. The study treatment is taken orally in 28 day cycles until either disease progression occurs or an unacceptable toxicity occurs. In addition to the study assessments to evaluate the disease, blood will be drawn to measure drug levels and biomarkers. Patients will be followed for survival at three month intervals after the end of treatment.


Investigator
John Pagel, MD, PhD
Location    
Seattle Cancer Care Alliance 800-804-8824  
Eligibility Criteria (must meet the following to participate in this study)
  • Subject has morphologically documented primary AML or AML secondary to myelodysplastic syndrome (MDS) as defined by the World Health Organization (WHO) criteria, as determined by pathology review at the treating institution and has relapsed or is refractory after 1 second line (salvage) regimen or after HSCT
  • Subject is positive for FLT3-ITD activating mutation in bone marrow or peripheral blood (>10% allelic ratio)
  • ECOG performance status of 0 to 2
  • In the absence of rapidly progressing disease clearly documented by the investigator, the interval from prior treatment to time of AC220 administration will be at least 2 weeks (14 days) for prior cytotoxic agents or at least 5 half-lives for prior noncytotoxic agents, including immunosuppressive therapy post HSCT
  • Persistent chronic clinically significant nonhematological toxicities from prior treatment (including chemotherapy, kinase inhibitors, immunotherapy, experimental agents, radiation, HSCT, or surgery) must be Grade ≤ 1
  • Patients - both males and females - with reproductive potential are eligible if the following criteria is met:
    • Female subject is:
    • Post-menopausal (defined as at least 2 years without menses) prior to Screening visit; or
    • surgically sterile (at least 1 month prior to Screening visit; or
    • of childbearing potential with contraception
    • Female subject of childbearing potential has a negative pregnancy test at the Screening visit and agrees to use contraception consisting of two forms of birth control (one of which must be a barrier method) throughout the study period
    • Male subject with partner(s) of childbearing potential must agree to use contraception consisting of two forms of birth control (one of which must be a barrier method) and agrees to no sperm donation throughout the study period
  • Subject must have adequate renal, hepatic, and coagulation parameters as indicated by the following laboratory values:
    • Aspartate aminotransferase (AST), and alanine aminotransferase (ALT) ≤ 2.5 x institutional upper limit of normal (ULN)
    • Total bilirubin ≤ 1.5 x institutional ULN
    • Serum creatinine ≤ 1.5 x institutional ULN and glomerular filtration rate (GFR) > 30 mL/min (calculated by Cockcroft and Gault formula).
Exclusions (conditions that would prevent participation in this study)
  • Subject received previous treatment with AC220
  • Subject has a diagnosis of acute promyelocytic leukemia
  • Subject has a diagnosis of chronic myelogenous leukemia (CML) in blast crisis
  • Subject has AML or antecedent MDS secondary to prior chemotherapy
  • Subject has had HSCT and has either of the following:
    • Is within 100 days of transplant
    • Is still taking immunosuppressive drugs
    • Has clinically significant graft-versus-host disease requiring treatment
    • Has Grade > 1 persistent non hematological toxicity related to the transplant
  • Donor lymphocyte infusion (DLI) is not permitted during the study or < 30 days prior to study entry
  • Subject has clinically active CNS leukemia. A subject is considered eligible if CNS leukemia is controlled and subject is receiving intrathecal (IT) therapy at study entry. Subjects should continue to receive IT therapy (or cranial radiation) as clinically indicated
  • Subject has received concurrent chemotherapy, immunotherapy, or radiotherapy within 14 days prior to the first dose of AC220, or any ancillary therapy that is considered to be investigational (i.e., used for non-approved indications(s) and in the context of a research investigation) within 30 days or 5 half-lives (whichever is longer) prior to the first dose of study drug
  • Subject requires treatment with concomitant drugs that prolong QT/QTc interval or with strong inhibitors or inducers of cytochrome P450- isozyme3A4 (CYP3A4) with the exception of antibiotics, antifungals, and antivirals that are used as standard of care post-transplant or to prevent or treat infections and other such drugs that are considered absolutely essential for the care of the subject
  • Subject requires treatment with anticoagulant therapy
  • Subject has a known positive test for human immunodeficiency virus, hepatitis C, or hepatitis B surface antigen
  • Subject had major surgery within 4 weeks prior to first dose of AC220
  • Subject has uncontrolled or significant cardiovascular disease, including
    • A myocardial infarction 12 months prior to the start of study drug;
    • Uncontrolled angina within 6 months prior to the start of study drug;
    • History of congestive heart failure (CHF) New York Heart Association (NYHA) class 3 or 4. If a screening echocardiogram (ECHO) or Multiple Gate Acquisition Scan (MUGA) is performed within 1 month prior to, or during study screening, and the result is a left ventricular ejection fraction (LVEF) that is ≥ 45% (or institutional lower limit of normal value); then this is not exclusionary
    • Heart rate <50 beats per minute at Screening ECG;
    • Diagnosed or suspected congenital long QT syndrome;
    • Known family history of congenital long QT syndrome;
    • QTc interval calculated by Fridericia's correction factor (QTcF) at Screening ≥ 450 ms. The QTcF will be derived from the average QTcF in triplicate;
    • Any history of second or third degree heart block;
    • Uncontrolled hypertension defined as systolic blood pressure ≥ 180 mmHg or diastolic blood pressure ≥ 110 mmHg;
    • Obligate need for a cardiac pacemaker or defibrillator;
    • Complete left bundle branch block;
    • Atrial fibrillation documented within 2 weeks prior to first dose of study drug; or
    • History of arrhythmia (multifocal premature ventricular contractions, bigeminy, trigeminy, ventricular tachycardia) that was symptomatic or required treatment (CTCAE Grade 3)
  • Subject has a pre-existing disorder predisposing the subject to a serious or life-threatening infection (e.g. cystic fibrosis, congenital or acquired immunodeficiency, bleeding disorder, or cytopenias not related to AML)
  • Subject has an active uncontrolled acute or chronic systemic fungal, bacterial, viral, or other infection
  • Subject has any of the following laboratory values:
    • Serum potassium < 4.0 mmol/L despite supplementation, or > 5.5 mmol/L
    • Serum magnesium below the institutional normal limit despite supplementation, or > 3 mg/dL (1.23 mmol/L)
    • Serum calcium >11.5 mg/dL (2.9 mmol/L) or ionized calcium >1.5 mmol/L
  • Subject is a female with a positive pregnancy test, pregnant, or breastfeeding
  • Subject has any medical, psychiatric, addictive or other kind of disorder which compromises the ability of the subject to give written informed consent and/or to comply with procedures
Last Updated
May 12, 2014
See this trial at ClinicalTrials.gov
Access protocol and consent forms at Fred Hutchinson Cancer Research Center
Disclaimer: We update this information regularly. However, what you read today may not be completely up to date.

Please remember:
  • Talk to your health care providers first before making decisions about your health care.
  • Whether you are eligible for a research study depends on many things. There are specific requirements to be in research studies. These requirements are different for each study.